LENSAR (LNSR) Competitors

LENSAR (NASDAQ:LNSR) and Iradimed (NASDAQ:IRMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

Does the MarketBeat Community favor LNSR or IRMD?

Iradimed received 254 more outperform votes than LENSAR when rated by MarketBeat users. Likewise, 65.49% of users gave Iradimed an outperform vote while only 37.50% of users gave LENSAR an outperform vote.

Company	Underperform	Outperform
LENSAR	Outperform Votes 6 37.50%	Underperform Votes 10 62.50%
Iradimed	Outperform Votes 260 65.49%	Underperform Votes 137 34.51%

Which has better valuation & earnings, LNSR or IRMD?

Iradimed has higher revenue and earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than Iradimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENSAR	$53.49M	3.08	-$14.38M	-$2.72	-5.14
Iradimed	$73.24M	9.19	$19.23M	$1.50	35.29

Do analysts rate LNSR or IRMD?

LENSAR currently has a consensus price target of $15.00, indicating a potential upside of 7.22%. Iradimed has a consensus price target of $72.00, indicating a potential upside of 36.00%. Given Iradimed's stronger consensus rating and higher probable upside, analysts plainly believe Iradimed is more favorable than LENSAR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENSAR	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Iradimed	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is LNSR or IRMD more profitable?

Iradimed has a net margin of 26.26% compared to LENSAR's net margin of -34.03%. Iradimed's return on equity of 24.12% beat LENSAR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENSAR	-34.03%	-49.02%	-21.12%
Iradimed	26.26%	24.12%	21.20%

Does the media prefer LNSR or IRMD?

In the previous week, LENSAR had 1 more articles in the media than Iradimed. MarketBeat recorded 7 mentions for LENSAR and 6 mentions for Iradimed. LENSAR's average media sentiment score of 1.01 beat Iradimed's score of 0.91 indicating that LENSAR is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LENSAR	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Iradimed	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders believe in LNSR or IRMD?

40.2% of LENSAR shares are owned by institutional investors. Comparatively, 92.3% of Iradimed shares are owned by institutional investors. 66.0% of LENSAR shares are owned by insiders. Comparatively, 37.1% of Iradimed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Which has more volatility and risk, LNSR or IRMD?

LENSAR has a beta of 0.56, indicating that its share price is 44% less volatile than the S&P 500. Comparatively, Iradimed has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Summary

Iradimed beats LENSAR on 15 of the 18 factors compared between the two stocks.